Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan

Efficacy and Safety of Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan: A Phase III, Multicenter, Randomized, Double-blind, Parallel-controlled, 12-week Clinical Study

The main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with Sacubitril/Allisartan (240mg).

Study Overview

• Status: Completed
• Conditions: Essential Hypertension
• Intervention / Treatment: Drug: Experimental: Sacubitril/Allisartan and Amlodipine Group; Drug: Active Comparator: Sacubitril/Allisartan Group

• Study Type: Interventional
• Enrollment (Actual): 346
• Phase: Phase 3

Contacts and Locations

Study Locations

• China
  • Beijing Municipality
    • Beijing, Beijing Municipality, China, 100034
      • Peking University First Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patients 18-75 years old.
2. Confirmed diagnosis of essential hypertension.

3. Patients who meet one of the following criteria when screening:

   A. Treatment-naive patients (newly diagnosed essential hypertension, or patients with a prior hypertension history who have not taken any antihypertensive medication for at least 4 weeks prior to screening): mean seated systolic blood pressure (msSBP) ≥150 mmHg and <180 mmHg.

   B. Patients with irregular oral administration of Sacubitril/Allisartan (240 mg once daily) (treatment duration less than 4 weeks before screening, or more than 5 missed dosing days within the 4 weeks prior to screening): msSBP ≥140 mmHg and<180 mmHg.

   C. Patients on existing stable antihypertensive therapy (receiving a stable dose of another single-agent antihypertensive, free combination of two single-agent drugs, or single-pill fixed-dose combination containing two active ingredients for at least 4 weeks prior to screening): msSBP ≥140 mmHg and <180 mmHg, and the physician determines that switching treatment to Sacubitril/Allisartan (240 mg once daily) is clinically appropriate.

   D. Patients with essential hypertension who have been regularly treated with Sacubitril/Allisartan (240 mg once daily) for ≥4 weeks and have msSBP ≥140 mmHg and<180 mmHg.

4. At randomization, subjects must have msSBP ≥140 mmHg and <180 mmHg.
5. Subjects voluntarily participate in the trial and sign the written informed consent form.
6. For subjects enrolled for ambulatory blood pressure monitoring (ABPM): in addition to all above inclusion criteria, one further requirement must be satisfied: valid ABPM report with a 24-hour average blood pressure ≥130/80 mmHg. (Subjects failing to meet Criterion 6 remain eligible for the main trial without ABPM testing.)

Exclusion Criteria:

1. Severe hypertension (msSBP ≥180 mmHg and/or msDBP ≥110 mmHg).
2. History or confirmed diagnosis of secondary hypertension.
3. Concomitant use of three or more types of antihypertensive agents.
4. Personal history of angioedema induced by drugs or other causes.
5. Clinically significant abnormal laboratory findings, including but not limited to: serum potassium >5.5 mmol/L or <3.5 mmol/L; serum ALT and/or AST >2.5 × upper limit of normal (ULN); serum creatinine >1.5 × ULN; any other clinically significant laboratory abnormality deemed by the investigator likely to confound efficacy and/or safety assessment of the study.
6. Type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus .
7. Subjects with active malignant tumor.
8. History of substance abuse or excessive alcohol consumption within 6 months prior to screening.
9. Blood donation or major blood loss (>400 mL) within 3 months prior to screening, or clinically diagnosed hypovolemia.
10. Participation in any interventional clinical trial with investigational medicinal product or medical device within 3 months prior to screening.
11. Drug compliance during run-in period <80% or >120%.
12. Any other conditions deemed inappropriate for trial enrollment by the investigator that may interfere with efficacy and/or safety evaluation of the study, including but not limited to anticipated poor subject compliance or impractical regular follow-up due to long residential distance.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Test Group	Drug: Experimental: Sacubitril/Allisartan and Amlodipine Group; Drug: Sacubitril/Allisartan and Amlodipine
Active Comparator: Reference Group	Drug: Active Comparator: Sacubitril/Allisartan Group; Drug: Sacubitril/Allisartan

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The baseline change in mean seated systolic blood pressure (msSBP)	Change from baseline in mean seated systolic blood pressure (msSBP) after 12 weeks of randomized, double-blind treatment	at 12 weeks

Collaborators and Investigators

• Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): November 23, 2024
• Primary Completion (Actual): November 10, 2025
• Study Completion (Actual): November 24, 2025

Study Registration Dates

• First Submitted: July 9, 2026
• First Submitted That Met QC Criteria: July 9, 2026
• First Posted (Actual): July 15, 2026

Study Record Updates

• Last Update Posted (Actual): July 15, 2026
• Last Update Submitted That Met QC Criteria: July 9, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: Hypertension; Amlodipine; Sacubitril; Allisartan
• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Essential Hypertension; Hypertension
• Other Study ID Numbers: SAL0130A302

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No